Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285473 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Naltrexone For ME/CFS: Dose-Finding
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT07285473: Clinical Trial Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT07285473 is a Phase 2 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07285473, a Phase 2 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
Primary Outcome
This will be measured using weekly surveys.
Interventions
- DRUG Low-Dose Naltrexone, 1.5mg
- DRUG Low-Dose Naltrexone, 3.0mg
- DRUG Low-Dose Naltrexone, 4.5mg
- DRUG Low-Dose Naltrexone, 6.0mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 2 |
What is known before NCT07285473 opens enrollment
NCT07285473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 4 interventions - of which Low-Dose Naltrexone, 1.5mg is the first listed.
NCT07285473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07285473 about?
NCT07285473 is a clinical study titled "Low-Dose Naltrexone For ME/CFS: Dose-Finding". This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
What is the current status of trial NCT07285473?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-09-01. Estimated completion is 2028-04-01.
What interventions are being tested in trial NCT07285473?
The interventions under investigation include: Low-Dose Naltrexone, 1.5mg (DRUG), Low-Dose Naltrexone, 3.0mg (DRUG), Low-Dose Naltrexone, 4.5mg (DRUG), Low-Dose Naltrexone, 6.0mg (DRUG).
Who is sponsoring clinical trial NCT07285473?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07285473's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI